We are live on ! Find out more
BIOT

Biotech Acquisition Company Class A Ordinary Shares
BIOT

Delisted

BIOT was delisted on the 2nd of February, 2023.

Back to rankings

58 hedge funds and large institutions have $146M invested in Biotech Acquisition Company Class A Ordinary Shares in 2021 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 4 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 4

117% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 6

21% more capital invested

Capital invested by funds: $121M → $146M (+$25.8M)

14% more funds holding

Funds holding: 51 → 58 (+7)

Holders
58
Holders Change
+7
Holders Change %
+13.73%
% of All Funds
1.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
13
Reduced
4
Closed
6
Calls
$98K
Puts
–
Net Calls
+$98K
Net Calls Change
+$12K

Top Buyers

Rank Fund Capital Flow
1
SRCM
Sage Rock Capital Management
New York
+$5.56M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$3.36M
3
SCM
Saba Capital Management
New York
+$3.05M
4
RCM
Rivernorth Capital Management
Florida
+$2.18M
5
Marshall Wace
Marshall Wace
United Kingdom
+$2.09M

Top Sellers

Rank Fund Capital Flow
1
KSCM
Kamunting Street Capital Management
Florida
-$3.07M
2
RIA
RP Investment Advisors
Ontario, Canada
-$1.2M
3
TI
Telemetry Investments
New York
-$1.01M
4
MSU
Mizuho Securities USA
New York
-$559K
5
EAM
Exos Asset Management
New York
-$242K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of Montreal
26
Bank of Montreal
Ontario, Canada
$1.95M – – –
CH
27
CVI Holdings
Delaware
$1.95M – – –
WAM
28
Wolverine Asset Management
Illinois
$1.72M -$88.9K -9,168 -5%
Bank of America
29
Bank of America
North Carolina
$1.62M – – –
PMAM
30
Picton Mahoney Asset Management
Ontario, Canada
$1.46M +$1.45M +150,000 New
Alyeska Investment Group
31
Alyeska Investment Group
Illinois
$1.46M – – –
BCM
32
Basso Capital Management
Connecticut
$1.44M +$40.6K +4,193 +3%
TCM
33
Tenor Capital Management
New York
$1.4M – – –
Jane Street
34
Jane Street
New York
$1.31M +$22.4K +2,312 +2%
Millennium Management
35
Millennium Management
New York
$1.3M +$930K +96,000 +258%
WA
36
Whitebox Advisors
Minnesota
$1.22M – – –
Capstone Investment Advisors
37
Capstone Investment Advisors
New York
$1.15M +$1.15M +118,426 New
AA
38
AQR Arbitrage
Connecticut
$985K +$119K +12,283 +14%
CCA
39
Castle Creek Arbitrage
Colorado
$974K – – –
CP
40
Centerbridge Partners
New York
$974K – – –
LP
41
LMR Partners
United Kingdom
$974K – – –
FTCM
42
First Trust Capital Management
Illinois
$877K +$872K +90,000 New
DFCM
43
Dark Forest Capital Management
Puerto Rico
$724K +$720K +74,328 New
Susquehanna International Group
44
Susquehanna International Group
Pennsylvania
$591K +$1.74K +180 +0.3%
PP
45
Paloma Partners
Connecticut
$498K +$495K +51,100 New
LC
46
Littlejohn & Co
Connecticut
$487K – – –
SSA
47
Schonfeld Strategic Advisors
New York
$487K – – –
WRBC
48
W.R. Berkley Corp
Connecticut
$478K – – –
TI
49
Telemetry Investments
New York
$390K -$1.01M -104,683 -72%
NAM
50
Nexpoint Asset Management
Texas
$339K +$106K +10,981 +46%
1
2
3

BIOT Hedge Fund Activity: Q3 2021 in Review

58 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Class A Ordinary Shares (BIOT) for Q3 2021, worth a combined $146M — up 21% from $121M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new BIOT positions and 6 closed out — a net gain of 7 holders — while 13 added to existing stakes and 4 trimmed.

The largest buyer was Sage Rock Capital Management, opening a new position worth an estimated $5.56M. The largest seller was Kamunting Street Capital Management, exiting entirely with an estimated $3.07M sold.

  • 58 institutional investors held Biotech Acquisition Company Class A Ordinary Shares (BIOT) as of Q3 2021, up from 51 in Q2 2021.
  • Funds reported $146M of Biotech Acquisition Company Class A Ordinary Shares stock for Q3 2021, up 21% quarter-over-quarter.
  • 13 funds opened new Biotech Acquisition Company Class A Ordinary Shares positions in Q3 2021 and 6 closed out, a net change of +7 holders.
  • The largest Biotech Acquisition Company Class A Ordinary Shares buyer in Q3 2021 was Sage Rock Capital Management, an estimated $5.56M added.
  • The largest Biotech Acquisition Company Class A Ordinary Shares seller in Q3 2021 was Kamunting Street Capital Management, an estimated $3.07M sold.

Based on aggregated 13F filings for Q3 2021.